Skip to main content
Premium Trial:

Request an Annual Quote

Genentech: Aviv Regev

Aviv Regev will join Genentech as head of research and early development, effective August 1. She will replace Michael Varney, who will retire from his post at the end of July, and will also join Genentech's enlarged corporate executive committee. Regev is currently faculty chair, core institute member, and a member of the executive leadership team at the Broad Institute, as well as a professor of biology at the Massachusetts Institute of Technology and a Howard Hughes Medical Institute investigator. Prior to that, she was a Bauer fellow at the Center for Genomics Research at Harvard University. Regev holds a PhD in computational biology and a master of science degree from Tel Aviv University.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.